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Abstract Chronic hepatitis B (CHB) is one of the important public health problems 
worldwide.  Major advances have been made in the treatment of CHB during 
the past several years.  This article systemically reviews advances in the 
application of HBV DNA quantitation and three approved drugs for HBV 
treatment, and presents an updated and practical clinical approach to 
managing CHB.  Highly sensitive PCR-based quantitation of HBV DNA 
makes it possible to precisely determine pre-treatment HBV load and 
monitor HBV DNA response during treatment.  HBV DNA level, HBeAg 
status, degree of hepatic histological activity and fibrosis, and serum 
transaminases are the most important parameters in determining indication, 
regimen, and duration of HBV treatment.  Although interferon alfa-2b, 
lamivudine, and adefovir are all approved as initial HBV treatment, 
understanding the advantages and advantages of each agent is important in 
choosing the best treatment for each individual patient with CHB. 
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1. Introduction 
It is estimated that 350 million of individuals are infected by hepatitis B virus (HBV) worldwide.  Major advances have been 
made in the treatment of chronic hepatitis B (CHB) during the past several years.  While increased available therapeutic agents 
improve efficacy of HBV treatment, it is also important to understand the general principles in optimizing these therapies.  Several 
guidelines have been published on management of CHB that well summarized current standard practice [1-3].  Through a systematic 
review of the literature, this article is aimed to provide a step-wise updated and practical clinical approach to management of CHB. 
2. Clinical Presentation of Chronic HBV Infection 
As discussed by Drs. Zhang and Pan in this special issue, the clinical presentation of chronic HBV infection can be quite 
different ranging from inactive carrier status to HBV-cirrhosis or hepatocellular carcinoma (HCC).  Understanding the spectrum and 
clinical presentation of chronic HBV infection is prerequisite for optimizing HBV treatment.  Chronic HBV infection is defined as 
positive HBsAg for > 6 months that has been traditionally classified as the following subgroups [4-6]: 
Inactive HBV Carrier State   
This group of patients has positive HBsAg and a low level of HBV load (i.e. < 1 x 105 copies/ml).  Clinically, these patients 
have normal transaminases (i.e. ALT and AST) and no symptoms related to HBV infection.  Histologically, most patients do not 
have significant hepatitis. 
Three different outcomes have been described in inactive HBV carriers.  While 70-80% remain in inactive HBV carriers 
indefinitely, 10-20% may develop HBeAg-positive CHB presented with a high level of HBV DNA, elevated transaminases and 
hepatic inflammation.  Anti-HBe-positive hepatitis may occur in inactive HBV carriers, but the frequency of this transition remains 
unknown.  Approximately 0.5% of the inactive HBV carriers spontaneously lose HBsAg annually.  It should be noted that all HBV 
carriers are at increased risk of developing HCC. 
Chronic Hepatitis B (CHB)   
CHB is characterized by positive HBsAg for greater than 6 months, serum HBV DNA >1 x 106 copies/ml, and persistent or 
intermittent elevation of serum ALT/AST.  A liver biopsy in most of these patients shows chronic hepatitis.  Depending on HBeAg 
status, these patients can be further classified as following two subgroups: 
1) HBeAg-positive CHB  
Patients with HBeAg-positive CHB present with positive HBsAg and HBeAg in serum that is associated with active HBV 
replication, infectivity, and hepatic inflammation.  Depending on the mode of HBV transmission, spontaneous seroconversion from 
HBeAg to anti-HBe is variable.  Most patients underwent seroconversion remain sustained remission of HBV infection that is 
associated with normal transaminases and a low or undetectable level of serum HBV DNA although serum HBsAg may remain 
positive. 
2) HBeAg-negative CHB  
Patients with HBeAg-negative CHB present with positive HBsAg, but negative HBeAg in serum that is associated with active 
HBV replication, elevated transaminases, and hepatic inflammation.  Pathologically, it is secondary to mutant viral infection in HBV 
pre-core or pre-core promoter region.  The prevalence of HBeAg-negative CHB varies worldwide from 14% to 33%.  In patients 
with HBeAg-negative CHB, approximately half of the patients had serum HBV DNA < 105 copies/ml [19].  HBeAg-negative CHB 
is usually progressive and less responsive to HBV treatment. 
HBV-cirrhosis  
Approximately 20% of patients with CHB develop HBV-cirrhosis.  Although HBV-cirrhosis represents a continued progression 
of CHB, we classify it as a different subgroup because of different treatment approach.  HBV load varies in this group of patients 
although it is usually low.  Like those with CHB, patients with HBV-cirrhosis can be either HBeAg or anti-HBe positive.  Although 
thrombocytopenia, splenomegaly, and hypoalubuminemia are indicative of cirrhosis, a liver biopsy provides histological diagnosis.  
Patients with HBV-cirrhosis can be compensated or decompensated.  The later presents with esophageal bleeding, ascites, hepatic 
encephalopathy, severe hyperbilirulinemia, and/or coagulopathy.  Those with decompensated HBV-cirrhosis should be referred for 
liver transplant evaluation.   
3. Available HBV Therapies 
To date, the Food and Drug Administration (FDA) approved three treatments for chronic HBV infection in the United States.  
They are interferon (IFN) alfa-2b, lamivudine (LAM), and adefovir (ADV) [1-3, 7-10].  Table 1 summarizes a comparison of these 
three therapeutic agents.   
Interferon (IFN) alfa-2b  
As a potent immune modulator, IFN has both direct and indirect anti-HBV effect although its precise mechanisms remain to be 
defined.  IFN is the first FDA approved agent for HBV infection.  A meta-analysis showed that 33% of treated patients loss HBeAg 
compared to only 12% of controls [11].  In addition, 7.8% of treated subjects loss HBsAg versus only 1.8% of controls had 
spontaneous loss of HBsAg [11].  The response rate to IFN treatment varies in different ethnic groups.  Asian patients with normal 
ALT level respond poorly to this treatment.  Studies indicated that a prolonged course of IFN treatment may improve response rate 
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[12].  One clinical trial has reported pegylated-IFN alfa-2a further improved response rate in patients with HBeAg-positive CHB 
[13].  Although the results need to be reconfirmed by larger clinical trials, this might provide us with an additional option in 
managing CHB. 
The course of IFN treatment is usually 16–24 weeks that offers a small, but certain opportunity of HBsAg clearance.  Response 
to IFN treatment is usually durable.  Reactivation of HBV infection occurs in approximately 10-15% of patients who responded to 
treatment, most commonly within a year after discontinuing IFN treatment.  IFN is administrated by subcutaneous injection, 
associated with broad side effects, and represents an expensive treatment regimen. 
Lamivudine (LAM)  
As a nucleoside analogue, LAM inhibits HBV DNA replication by suppressing HBV DNA synthesis.  As summarized in table 
1, one-year of LAM treatment with 100 mg, once a day results in significant HBeAg seroconversion, suppression of HBV DNA, 
normalization of transaminases, and improved histology.  The overall response rate to one year of LAM treatment as determined by 
HBeAg seroconvertion is approximately 16% (vs. 4% in the placebo group) that is comparable to a full course of IFN treatment [8, 
11].  A prolonged course of LAM treatment further improves the response rate [14].  LAM represents a safe, cost-effective, and 
convenient HBV treatment regimen, but it does not result in HBsAg clearance and the response to LAM is less durable than that to 
IFN (Table 1).  It is well known that LAM treatment is associated with YMDD mutation in the region of HBV DNA polymerase that 
causes LAM resistance.  The incidence of YMDD mutation is treatment duration dependent, from 17% at 1-year treatment to 69% at 
5-years treatment [1-3]. 
Adefovir (ADV) Dipivoxil  
ADV dipivoxil is a prodrug of ADV and a nucleotide analogue of adenosine monophosphate that inhibits HBV DNA 
replication by suppressing HBV DNA polymerase.  One year of ADV treatment with 10 mg, once a day results in significant 
HBeAg seroconversion, suppression of HBV DNA, normalization of transaminases, and improved histology.  The overall response 
to one year of ADV treatment as determined by HBeAg seroconversion is approximately 12% (vs. 6% in placebo group) that could 
be increased to 23% by the end of 2-year treatment [9].  In addition, ADV has been demonstrated as an effective treatment of 
HBeAg-negative CHB.  In these patients, undetectable serum HBV DNA was achieved in 46% and 51% of these patients after 48 
and 98 weeks of ADV treatment, respectively [10].  Recent studies have demonstrated successful rescue therapy with ADV in 
patients who develop YMDD mutation [15, 16]. 
In contrast to LAM, the incidence of ADV-related HBV mutation and drug resistance is extremely low.  For instance, the 
emergence of ADV resistant mutation, N236T, was only 1.8 and 3.9% in patients who received 2 and 3 years of this treatment, 
respectively [17, 18].  Thus, ADV offers a unique advantage in patients who need a prolonged course of HBV treatment, especially 
those with HBeAg-negative CHB [10] and those with decompensated cirrhosis and are listed for or have received a liver 
transplantation [15].  Patients who develop ADV resistant mutation remain sensitive to LAM treatment [16].   
4. Indications of HBV Treatment 
Historically, levels of HBV DNA and ALT, and histological activity of liver biopsy have been used as the three main factors to 
determine if a patient needs HBV treatment or not [1-3]. 
HBV DNA Levels  
It is known that HBV is not directly pathogenic to hepatocytes and host immune response to HBV antigens expressed on the 
infected hepatocytes is the principle determinants of the liver injury.  Thus, a high HBV load has been the primary indication for 
HBV infection.  However, the threshold HBV level that is associated with progressive liver disease remains to be determined.  In 
addition, patients with CHB may have fluctuating HBV DNA levels.  A study revealed that only one third of patients with HBeAg-
negative CHB and elevated ALT had HBV DNA levels persistently > 105 copies/ml [19].  This suggested that an even lower HBV 
DNA threshold might be reasonable to indicate HBV treatment in patients HBeAg-negative CHB.  Thus, it has recently been 
recommended that different HBV DNA levels should be used to determine HBV treatment depending on HBeAg status and clinical 
presentation of CHB [3].  As summarized in Figure 1, HBV treatment should be considered in patients with HBeAg-positive CHB 
and HBV DNA > 105 copies/ml in combination with elevated ALT level and histological activity.  While in patients with HBeAg 
negative-CHB and patients with compensated HBV cirrhosis regardless HBeAg status, HBV treatment should be considered when 
HBV DNA > 104 copies/ml [3].  It should be noted that above cutoff HBV DNA levels are arbitrarily made based on limited 
research results, and not endorsed by all guidelines [1-3].  Additional studies will be needed to verify these criteria. 
Histological Activity and Stage  
Liver biopsy provides us with valuable information of histological activity and stage of HBV disease in patients with HBV 
infection.  It is known that patients with chronic HBV infection and active hepatic inflammation carry a significantly higher risk of 
disease progression.  Histological staging of HBV disease is clinically very valuable in assessing degree of fibrosis and predicting 
disease progression.  Good response to HBV treatment has been well associated with improved histology.  Therefore, a pre-HBV 
treatment liver biopsy is usually preferred by most hepatologists.  However, for those with clear-cut indications for HBV treatment, 
a liver biopsy may not be necessary.  As it will be discussed below, histological assessment is very valuable in determining HBV 
treatment in patients with persistently normal transaminases. 
ALT Levels  
For many years, ALT has been used as a standard surrogate for the activity of CHB.  Thus, ALT level in combination with 
HBV DNA level and histological activity has been used as a determinant for HBV treatment [1-3].  It is well accepted that elevated 
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ALT should be used as one of the determinants for HBV treatment in patients with CHB.  However, it remains controversial on at 
what level of ALT elevation a patient with CHB should be considered for HBV treatment [3].   
On the other hand, patients with detectable HBV load (i.e. by HBV hybridization or HBV > 105 copies/ml), but persistently 
normal transaminases have historically not been considered as candidates for HBV treatment based on the assumption that these 
patients usually have a slow progression and evidence that these patients usually have a low response rate to HBV treatments.  
However, the extent of liver injury and fibrosis is not always correlated with ALT levels [20].  Furthermore, a sustained suppression 
of HBV replication is now more achievable than before.  In addition, an active HBV replication has been associated with increased 
risk for HCC [21].  Thus, it has become more accepted that a normal ALT level alone should not be used to determine HBV 
treatment in these patients.  Instead, in patients with HBV DNA > 105 copies/ml and persistently normal ALT levels, a liver biopsy 
might be considered (Figure 1).  If active liver inflammation or advanced fibrosis is histologically confirmed, the patient should be 
considered for HBV treatment.  Additional studies will be needed to further assess the efficacy and benefit of HBV treatment in this 
group of patients. 
5. Goals of HBV Treatment 
The rationale of HBV treatment is to significantly suppress HBV replication and prevent the progression of HBV-mediated 
liver injury that may cause cirrhosis, liver failure, or HCC.  Therefore, the primary goal of HBV treatment should focus on 
maintaining sustained HBV DNA suppression.  This will lead to the other benefits, i.e. the secondary aims of therapy, including 
normalization of transaminases, histological improvement, reduction of cirrhosis and the related complications, and the need of liver 
transplantation [1-3]. 
For patients with HBeAg-positive CHB, HBeAg seroconversion to anti-HBe has been associated with a durable and sustained 
HBV suppression.  Hence, this has been used as an end point of the treatment in this group of patients.  It has been reported that 
cirrhosis may occur in those who discontinued HBV treatment after achieved HBeAg seroconversion.  However, it remains unclear 
whether maintenance HBV treatment will further slow down disease progression in these patients.  For patients with HBeAg-
negative CHB, seroconversion of HBeAg is absent and discontinuation of this treatment is associated with high incidence of HBV 
relapse.  Thus, a long-term treatment to maintain sustained HBV suppression is usually necessary in these patients.  Although loss of 
HBsAg is desirable, it is rarely achieved with currently available HBV treatments.  Thus, loss of HBsAg is not one of the common 
goals for HBV treatments.   
6. Predictors of HBV Treatment Response 
Knowing clinical, biochemical, and virological predictive factors to HBV treatment response is important for planning and 
monitoring HBV treatment.  A low level of pre-treatment serum HBV DNA, high levels of ALT and histological activity, a history 
of adulthood HBV infection, and non-Asian ethnic origin have been associated with higher sustained response rates to IFN treatment 
[22].  Duration of IFN treatment also affects response.  For instance, 32- weeks treatment is superior to 16 weeks treatment [12].  
The predictors of response to LAM and ADV therapies are similar to those for IFN except that baseline HBV DNA may not be very 
important. 
7. Individualization of HBV Treatment 
As summarized in Table 1 and Figure 1, although IFN, LAM, and ADV are all FDA approved agents for HBV treatment, the 
differences in drug administration, duration and efficacy of the treatment, frequency of drug resistance, and cost do exist in these 
three drugs.  Thus, an HBV treatment should be tailored based on the type of chronic HBV infection, host, virus, and drug-related 
factors.  Although it remains controversial, most published guidelines recommend the following principles in choosing HBV 
treatment [1-3]. 
In patients with HBeAg-positive CHB, LAM, ADV, and IFN are all the first line of HBV treatment.  Overall, LAM and ADV 
are probably more favorable due to convenient administration, better tolerance, and less cost.  When planning a LAM treatment, 
medical adherence and regular follow-up should be assured because of a relatively high frequency of drug-resistant mutation and 
flare of HBV disease.  IFN treatment might be an option for those who prefer a shorter and definitive course of HBV treatment. 
To date, there is no study indicating a significant difference of treatment response in these three drugs in patients with HBeAg-
negative CHB.  However, these patients carry a high incidence of relapse after the treatment is discontinued.  Thus, these patients 
usually need a prolonged course of HBV treatment.  As a convenient regimen with extremely low frequency of HBV mutation and 
drug resistance, ADV is a preferred treatment regimen in these patients. 
Likewise, patients with HBV cirrhosis, especially hepatic decompensation and listed for liver transplantation, and patients who 
underwent liver transplantation usually need a prolonged course of HBV treatment.  In addition, any episode of HBV disease flare 
induced by drug resistance could negatively impact outcomes in these patients.  Clearly, ADV is a preferred treatment regimen in 
these patients.  A recent study has shown that ADV treatment is effective and well tolerated in this group of patients [15].  A high 
frequency of YMDD mutation and flare of HBV disease has been demonstrated when LAM was used in this group of patients.  IFN 
is usually poorly tolerated and could induce hepatic decompensation, and therefore relatively contraindicated in this group of 
patients. 
The value of combination HBV treatment remains to be determined.  Results on efficacy of IFN and LAM combination have 
been inconsistent.  Combination of LAM with ADV appears not synergistic.  However, a brief course of combination of LAM with 
ADV is thought reasonable to reduce flare when dealing with drug resistance and planning switch these two drugs. 
8. On-treatment Monitoring and Duration of Therapy 
Patients who receive HBV treatment should be monitored regularly.  The interval of follow-up visits may vary depending on 
regimen and duration of the HBV treatment.  For instance, those on IFN therapy may need to be monitored every 4-6 weeks, but 
those on LAM or ADV should be monitored every 3-6 months.  On-treatment monitoring should focus on medical adherence and 
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tolerance, biochemical and virological responses to these treatments.  Comparing to HCV treatment, the frequency needed for 
follow-up HBV DNA measurement is less defined during HBV treatment.  However, it is recommended whenever a breakthrough of 
ALT and other liver tests or clinical deterioration occurs during the treatment.  A rising or relapse of HBV DNA level indicates drug 
resistance.  Special assays of drug resistance related HBV DNA mutation provide virological evidence of this diagnosis. 
Currently recommended duration of IFN treatment is 16-24 weeks.  It remains to be determined whether a prolonged course of 
this treatment may further improve the response rate, but this might not be practical due to a high frequency of IFN- induced adverse 
effects.  For patients with HBeAg-positive CHB, HBeAg seroconversion to anti-HBe has been used as an end point of both ALM 
and ADV treatments.  The finding that the virologic response to LAM treatment is less durable than that to IFN treatment raised a 
question whether LAM treatment should be continued after HBeAg seroconversion to anti-HBe.  It was reported that additional 3-6 
months of LAM treatment after HBeAg seroconversion could further sustain virologic response in these patients [3].  Thus, it is 
recommended that LAM treatment should be continued for additional 3-6 months after HBeAg seroconversion is confirmed [2, 3].  
Preliminary data suggested that HBeAg seroconversion appears associated with a durable virologic response to ADV treatment [23].  
Long-term ADV or LAM treatment is usually needed in patients with HBeAg-negative CHB and those with decompensated HBV 
liver disease no matter their candidacy for liver transplantation.  Additional studies are needed on how to individualize HBV 
treatment in these patients.  
9. HBV Treatment in Special Patient Groups 
Chronic HBV Infection with Persistently Normal Transaminases  
Chronic HBV infection may present with high level of serum HBV DNA, but persistently normal transaminases.  These 
patients usually have milder hepatic inflammation and tend to have a poor serological response to antiviral therapy.  Thus, this group 
of patients is traditionally not considered for HBV treatment [1-3].  However, it is well known that there is increased risk of 
developing HCC and flare of HBV disease in these patients [4, 21].  Histologically, some of these patients have significant hepatic 
inflammation and fibrosis [20].  Therefore, it is now recommended that a liver biopsy should be considered in these patients [3].  For 
those who have histological evidence of active and/or advanced HBV disease, HBV treatment should be considered (Figure 1) [3].  
Although it is known that these patients respond a standard course of HBV treatment poorly, additional study is necessary to assess 
whether a prolonged course of HBV treatment improves virological response in these patients. 
HBV and HIV Coinfection  
It is known that HIV infection negatively impact the natural course of CHB, resulting in a more progressive HBV disease, 
increased incidence of HBV cirrhosis, and liver-related mortality.  Although HBV treatment is usually highly indicated, clinical 
trials of HBV treatment remains limited in this special group of patients.  The available preliminary studies indicated that the 
response rate of these patients to HBV treatment is low and less durable, especially those with a low CD4 account.  However, it 
should be noted that most of these studies involved small cohort of patients, lacking a proper control, or reported a short-term 
observation.  Thus, effort should be made to conduct multicenter, randomized clinical trials to assess the efficacy of available HBV 
treatments and define optimal treatment regimens in this group of patients.  Several articles have systematically reviewed current 
literatures and provided recommendations on managing HBV disease in these patients [24, 25]. 
HBV Infection and Immunosuppressive Therapy or Cancer Chemotherapy  
Approximately 20-50% of HBV carriers undergoing immunosuppressive therapy or cancer chemotherapy develop reactivation 
of HBV replication presented with hepatitis flare and rarely hepatic decompensation [26, 27].  This may occur even in those with 
occult HBV infection [28].  Administration of LAM prior to these treatments is associated with reduced frequency and severity of 
hepatitis B flare and improved survival in these patients [26, 29]. 
HBV Infection and Pregnancy  
Both LAM and ADV are classified as category C, meaning certain risk for fetus during pregnancy.  Although these is no 
consensus on managing HBV disease in female patients who plan to become pregnancy, several options have been proposed: (1) 
postpone HBV treatment if HBV DNA is low and disease activity is mild; (2) A full course of IFN treatment may be attempted for a 
possible virologic response; (3) start HBV treatment during third trimester to prevent HBV transmission.  Two small studies, 
including a randomized study, suggested that LAM treatment started in third trimester is safe and effective in reducing HBV 
perinatal transmission [30, 31].  However, LAM treatment should be combined with hepatitis B immnoglobulin and HBV 
vaccination of the newborns.  In addition, another study indicated that it appears safe to continue LAM treatment in patients who 
became pregnant while receiving LAM treatment [32].  The safety of ADV in pregnant patients remains unknown.  It is 
recommended that any patients treated with LAM or ADV should be reported to the respective pregnancy registry [3]. 
HBV Infection and Liver Transplantation  
Patients with HBV end-stage liver disease carry an increased risk of recurrent HBV infection after liver transplantation.  In 
addition, utilization of anti-HBc positive organs could develop HBV infection in the recipients.  Management of these two clinical 
entities will be discussed by Dr. Vierling in a separated article in this special HBV issue. 
10. Research Directions 
Although significant advances have been made in managing HBV infection, challenge remains in optimizing HBV therapy.  
First, further understanding HBV dynamics and correlation of the level of HBV replication with liver injury will be invaluable for us 
to define an evidence-based indication of HBV treatment in HBeAg-positive and HBeAg-negative chronic HBV infection.  Second, 
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several nucleoti(si)de analogues are being tested as new anti-HBV agents, such as entecavir, telbivudine, and clevudine [33, 34].  
This may offer us possibility to better individualize HBV treatment based on patient’s condition and viral profile (i.e. drug 
resistance).  Third, although early studies did not demonstrate improved treatment response [35], ongoing studies using modified 
regiments of combination HBV therapy may prove to be more effective and less drug resistant.  All these will further improve the 
management of CHB. 
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Tables and Figures 
Table 1. Comparison of Three US FDA Approved Treatments for CHB [2, 3, 18, 23] 
Parameters Interferon Lamivudine Adefovir 
Dosing regimen 5 MU/day, or 10 MU/TIW 100 mg/day 10 mg/day 
Duration of treatment    
HBeAg + CHB 4-6 months > 1 year > 1 year 
HBeAg - CHB 1 year > 1 year > 1 year 
HBeAg seroconversion (%) (In 
HBeAg + CHB) 
18 16-18 (After 1 year 
treatment) 
12 (After 1 year treatment) 
Durability of response (%) 
   (After HBeAg seroconversion) 
80-90 (At 4-8 years) 77 (At 3 year) 91 (At a mean of 55 weeks) 
Route of administration Subcutaneous Oral Oral 
Tolerability Poor Good Good 
Cost High Low Intermediate 
MU: Million international unit; TIW: Three times a week. 
Figure 1. Algorithm for the management of chronic HBV infection [2, 3].  
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